A carregar...
The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma
BACKGROUND: Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene are present in approximately 50% of melanomas. The selective BRAF inhibitor vemurafenib has demonstrated significant clinical benefits in patients with melanomas harboring the most common...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4192296/ https://ncbi.nlm.nih.gov/pubmed/25265970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-727 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|